1. Pink Sheet
  2. >>Geography
  3. >>Europe
  4. >>United Kingdom

U.K. Cancer Drug Fund May Shift To ‘Coverage With Evidence Development’-Style Approach

 
• By John Davis

Fund would revaluate benefits – and pricing – of drugs it covers, adding extra layer of complexity to accessing new medicines for Britain’s cancer patients.

With the U.K.’s Cancer Drugs Fund (CDF) being rapidly emptied by the inclusion of new drugs with ever higher prices it was probably only a matter of time before the British government and the publicly-funded National Health Service would propose a role for the CDF in re-evaluating drugs and negotiating prices with industry.

The NHS in England and its Clinical Reference Group for Chemotherapy (CFG-C) are proposing that the CFG-C’s panel of expert...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

UK Regulator Expands Team To Assess Computer-Simulated Trials

 
• By Eliza Slawther

The UK MHRA is looking to support drug sponsors in using in silico data during the drug development process – a move that will reduce the use of animal models.

ACCESS Consortium To Harmonize Clinical Trial Process Across Five Nations

 
• By Eliza Slawther

Clinical trial sponsors could soon benefit from a streamlined clinical trial approval process in Australia, Canada, Singapore, Switzerland and the UK under a new ACCESS Consortium project.

ViiV Secures English Funding For First Long-Acting HIV Prevention Injection

 
• By Neena Brizmohun

The National Health Service said the roll out of ViiV Healthcare’s Apretude would bring England closer to its aim of becoming the first country in the world to end HIV transmissions by 2030.

UK Must Make ‘Strategic Choices’ To Free Up Money For Medicines, ABPI Chief Says

 
• By Eliza Slawther

The UK’s commercial environment is “incredibly strained,” meaning that there is little money left to pay for innovative medicines. The ABPI’s chief executive says a “fundamental transformation” will be required to drive necessary changes.

More from Europe

EMA Slashes Average Clock-Stop Extensions By 18% To Speed Up Drug Reviews

 
• By Vibha Sharma

The European Medicines Agency says it is speeding up its review of drug marketing applications through initiatives that restrict requests from companies for additional response time and minimize unnecessary questions from the assessors.

EMA Backs Insmed’s Brinsupri And Sanofi’s Wayrilz, Rejects Rezurock

 
• By Eliza Slawther

The European Medicines Agency’s human medicines committee, the CHMP, has recommended Insmed’s Brinsupri and Sanofi’s Wayrilz for pan-EU approval but turned down Sanofi’s Rezurock based on trial results that cast doubt on the drug’s efficacy.

ViiV Secures English Funding For First Long-Acting HIV Prevention Injection

 
• By Neena Brizmohun

The National Health Service said the roll out of ViiV Healthcare’s Apretude would bring England closer to its aim of becoming the first country in the world to end HIV transmissions by 2030.